Results 21 to 30 of about 54,210 (294)

A case report of pulmonary amyloidosis recognized by detection of AA amyloid exclusively in alveolar macrophages [PDF]

, 2020
Amyloidosis is a rare condition in which tissue deposits of inert fibrillar protein result in organ damage and dysfunction. There are several types of amyloid fibrils.
Bychkov, Andrey, Tanaka, Kei, Mukae, Hiroshi, Fukuoka, Junya, Ando, Kouji, Zaizen, Yoshiaki, Ishimoto, Hiroshi, Tabata, Kazuhiro, Miyazaki, Yasushi, Laohawetwanit, Thiyaphat   +9 more
core   +1 more source

Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]

, 2012
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Grützmacher, Peter, Oliver Jung, Christoph Stephan, Markus Bickel, Peter Gruetzmacher, Kerstin Amann, Hans Stefan Haack, Jung, Oliver, Haack, Hans Stefan, Büttner, Maike, Stephan, Christoph, Bickel, Markus, Amann, Kerstin, Amann, Kerstin Ute, Betz, Christoph, Maike Buettner, Haack, Hans S., Christoph Betz   +17 more
core   +1 more source

Evaluation of peripheral amyloid neuropathy

Неврология, нейропсихиатрия, психосоматика, 2021
Symptoms of peripheral nervous system (PNS) damage are common clinical manifestations of systemic amyloidosis. Peripheral amyloid neuropathy is characterized by a progressive course, leading to the disability of patients; however, the current ...
O. E. Zinovyeva, E. I. Safiulina, N. S. Shcheglova, Z. V. Surnina, A. M. Nosovskiy   +4 more
doaj   +1 more source

Purpuric halo around hemangioma as a clue for primary systemic amyloidosis: Case report and review of literature

Dermatologica Sinica, 2018
Mucocutaneous lesion appears in up to 40% of patients with primary systemic amyloidosis (AL amyloidosis). The cutaneous signs may be co-expressed with other organ involvement or even solely presented as the first clue.
Yin-Shuo Chang, Kuo-Hsien Wang, Hsiou-Hsin Tsai, Chung-Hong Hu, Jan-Show Chu   +4 more
doaj   +1 more source

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

Hematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen, Haifei Chen, Lingyun Zhou, Danbo Liu, Fang Du, Hongxian Xiang   +5 more
doaj   +1 more source

Search for AL amyloidosis risk factors using Mendelian randomization. [PDF]

, 2023
In amyloid light chain (AL) amyloidosis, amyloid fibrils derived from immunoglobulin light chain are deposited in many organs, interfering with their function. The etiology of AL amyloidosis is poorly understood. Summary data from genome-wide association
Chattopadhyay, S, Schmidt, B, Goldschmidt, H, Milani, P, Jöckel, K-H, Merlini, G, Försti, A, Rowcieno, D, Hegenbart, U, Wechalekar, A, Palladini, G, Hemminki, K, Hoffmann, P, Nöthen, MM, Hawkins, P, Schönland, SO, Saunders, CN, Landi, S, Houlston, R, Huhn, S, Weinhold, N   +20 more
core   +2 more sources

Amyloidosis – short review

Journal of Medical Science, 2016
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type.
Agnieszka Danuta Gaczkowska, Paweł Jagodziński, Adrianna Mostowska   +2 more
doaj   +1 more source

Prognosis and Staging of AL Amyloidosis [PDF]

Acta Haematologica, 2020
The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly.
Tobias, Dittrich, Christoph, Kimmich, Ute, Hegenbart, Stefan O, Schönland   +3 more
openaire   +2 more sources

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease

Hematology/Oncology and Stem Cell Therapy, 2019
Introduction: Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficiency. However, it is not very clear who develops aFX deficiency in AL amyloidosis.
Gina Patel, Parameswaran Hari, Aniko Szabo, Lisa Rein, Lisa Baumann Kreuziger, Saurabh Chhabra, Binod Dhakal, Anita D’Souza   +7 more
doaj   +1 more source

Supportive Care in AL Amyloidosis [PDF]

Acta Haematologica, 2020
Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response.
M Teresa, Cibeira, José T, Ortiz-Pérez, Luis F, Quintana, Carlos, Fernádez de Larrea, Natalia, Tovar, Joan, Bladé   +5 more
openaire   +2 more sources